trial

Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder

NCTId NCT01280305
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 200 (estimated)
Sponsored by Sheba Medical Center
Primary completion 2012-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
200 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-03
Primary completion
2012-12
Eligibility
FEMALE · 45 Years · 65 Years

Interventions & indications

Drugs
Raloxifene

Sponsors

Sheba Medical CenterLead Sponsor

Investigators

1
Mark Weiser, MDPrincipal Investigator

Sites

13 total
Ramat Gan, IsraelArad, RomaniaBotoșani, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaCluj-Napoca, RomaniaCluj-Napoca, Romania

Linked catalysts

1
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder — primary completion2012-12

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE3
Primary Completion Date
2012-12
Status
UNKNOWN
relationships
The graph out of here
drug
Raloxifene
drug
lead_sponsor
Sheba Medical Center
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Mark Weiser, MD
person